Antibiotics are widely used to treat infections in humans. However, the impact of antibiotic 27 use on host cells is understudied. We have identified a novel antiviral effect of commonly 28 used aminoglycoside antibiotics. We show that mucosal application of aminoglycosides 29 
Introduction 43
Antibiotics comprise a large and complex group of compounds typically secreted by 44 bacteria targeting other prokaryotes. Antibiotics have revolutionized medicine since its 45 discovery. However, overuse and misuse of antibiotics have led to the emergence of 46 resistant bacteria in humans and in livestock. Current medicine faces a dire threat of 47 antibiotic resistant bacteria, which is rampant in many hospitals around the world. In 48 addition to its microbicidal activities, antibiotics can also directly affect mammalian cells in 49 a variety of ways. Antibiotics have been reported to directly inhibit eukaryotic translation 1 , 50 inhibit mitochondrial function 2,3 and induce changes in mammalian metabolic pathways 4 . 51
There is a critical need to better understand the host effects of commonly used antibiotics. 52
53
Here, we found that topical delivery of an aminoglycoside antibiotic to the mucosa induced 54 significant alteration of host gene expression, inducing increased expression of antiviral 55 interferon-stimulated genes (ISGs). Aminoglycoside-mediated ISG induction resulted in 56 significant protection against genital HSV-2 infection and significantly reduced Zika virus 57 replication. Aminoglycoside-mediated antiviral protection was independent of the host 58 microbiota, as intravaginal aminoglycoside treatment protected germ-free mice form HSV-59 2 infection. This protection mechanism operates in the vaginal mucosa and nasal mucosa, 60 as intranasal aminoglycoside treatment increased ISG expression in the lung and 61 aminoglycoside pre-treated hosts had increased survival after highly virulent influenza A 62 virus infection. ISG expression was dependent on TLR3 and downstream signaling 63 pathway, and robust recruitment of TLR3-expressing XCR1+ dendritic cells to the vaginal 64 mucosa. Our results reveal an unexpected induction of antiviral state by commonly used 65 aminoglycoside antibiotics. 66
Vaginal neomycin treatment induces expression of interferon-stimulated genes 118
To elucidate the mechanisms underlying neomycin-mediated host resistance against HSV-119 2, we analyzed vaginal gene transcription in neomycin-treated mice prior to infection. We 120 identified over a hundred significantly upregulated genes ( Fig. 2a ; Supplementary Table  121 1). No genes were significantly downregulated in expression. Using Ingenuity pathway 122 analysis, we found that genes in the type I interferon (IFN) pathway were heavily enriched 123 (Fig. 2b) , with over 30% of the upregulated genes falling within this pathway. We 124 independently confirmed the upregulation of a subset of IFN-stimulated-genes (ISGs) 125 using RT-qPCR (Fig. 2c) . ISG expression was also increased in germ-free mice upon 126 neomycin treatment ( Supplementary Fig. 2 ). Neomycin-induced ISG expression was rapid, 127 as a single treatment was sufficient to significantly increase ISG expression 2-5 fold 128 though not to the levels observed after a week's treatment (8-10 fold) ( Supplementary Fig.  129 3a). Neomycin-mediated ISG induction was also dose-dependent as increased amounts of 130 neomycin correspondingly increased ISG expression ( Supplementary Fig. 3a ). Significant 131 ISG induction was maintained up to 3 days after neomycin treatment and was only partially 132 lost by 1 week post neomycin treatment with 5 of 8 genes still significantly upregulated 133 ( Supplementary Fig. 3c ). Finally, this neomycin-mediated ISG induction was restricted to 134 the site of application, as we observed no upregulation of ISG expression in the lungs of 135 neomycin-treated mice ( Supplementary Fig. 3d ). 136 137
Most, but not all, aminoglycosides induce ISG expression. 138
Neomycin is a member of a large and diverse group of aminoglycosides, many of which 139 are commonly used to treat bacterial infection. To determine if ISG induction was common 140 across the aminoglycoside family, we treated mice with a panel of structurally diverse 141 aminoglycosides for 1-2 days. Five out of the seven aminoglycosides we tested 142 significantly increased ISG expression upon application to the vaginal mucosa (Fig. 2d) . 143
The two non-inducers were streptomycin, which contains a streptamine core distinct from 144 the other 2-deoxystreptamine-containing aminoglycosides, and amikacin, a kanamycin 145 homolog that contains an addition L-haba side chain 10 . Thus, the majority of the 146 aminoglycosides tested induce ISG expression upon application to the vaginal mucosa. 147
Since aminoglycosides mediate their antibiotic activity by binding ribosomal RNA, we 148 tested if this ISG-induction was observed in other non-aminoglycoside ribosomal-targeting 149 antibiotics 11 . Mice were treated intravaginally with tetracycline or chloramphenicol, 150 compounds that inhibit bacterial protein synthesis by binding the 50s ribosome subunit Fig. 4c ). 157
To determine the link between ISG expression and antiviral protection, we compared the 158 ability of ISG-inducing and non-ISG inducing aminoglycosides to protect mice against 159 HSV-2 infection. We selected two ISG-inducing aminoglycosides (kasugamycin, sisomicin) 160 as well as the two non-ISG inducing aminoglycosides (amikacin, streptomycin). Mice pre-161 treated with non-ISG inducers were not protected against HSV-2 infection, with vaginal 162 viral titers and disease scores equivalent to those of PBS-treated control mice (Fig. 2e,f) . 163
Kasugamycin and sisomicin treatment however, resulted in significant reduction in vaginal 164 viral titers and disease scores, displaying equivalent levels of antiviral protection as 165 compared to neomycin (Fig. 2e,f) . These data indicated that ISG induction by 166 aminoglycosides corresponds to their ability to protect mice against viral challenge. 167
Aminoglycosides induce antiviral protection against RNA and DNA viruses across 168 multiple mucosal surfaces. 169 Next, we examined if aminoglycoside-mediated induction of antiviral immunity was specific 170 to the vaginal tract or if similar protection could be observed in other mucosal surfaces 171 such as the respiratory tract. A single intranasal dose of neomycin sufficed to significantly 172 upregulate ISG expression in the lung (Fig. 3a) . To determine if this ISG induction results 173 in host antiviral resistance, we tested neomycin-mediated protection in a functionally 174 relevant mouse model of influenza infection. Many inbred mouse strains, including 175 C57BL/6, lack Mx1 (Ref. 13 ). Mx1 encodes the myxovirus resistance protein 1, a dynamin-176 like GTPase that blocks primary transcription of influenza by binding to viral nucleoproteins 177 [14] [15] [16] [17] . Mx1 is an ISG that is induced by neomycin treatment (Fig. 3a) , and when expressed, 178 confers resistance to influenza A virus in mice 14 . In mice lacking Mx1 such as C57BL/6 179 strains, innate resistance to influenza is abrogated, and they rely on adaptive immunity. 180
We previously showed that oral neomycin treatment renders Mx1 deficient mice 181 susceptible to influenza disease because it depletes gut commensal bacteria that normally 182 support the function of dendritic cells that prime CD8 T cells 18 . In contrast, in this study, 183
we used Mx1 congenic mice, which are highly resistant to influenza virus. The use of Mx1 184 congenic mice allowed us to study the ability of intranasal neomycin to elicit innate antiviral 185 resistance, through inducing expression of ISGs including Mx1. To determine if neomycin-186 mediated ISG induction was sufficient to confer protection, we infected neomycin-187 pretreated Mx1 congenic mice with a highly virulent influenza A virus A/PR8 (hvPR8), 188 which was selected for its ability to replicate rapidly even in the presence of Mx1 (Ref. 19 ). A 189 single dose of neomycin was sufficient to significantly increase survival following challenge 190 with an otherwise lethal dose of hvPR8, with 50% of mice protected (Fig. 3b) . These 191 results demonstrate that mucosal application of a single dose of neomycin can result in 192 substantial protection against a highly virulent influenza A virus infection. 193
We also tested the ability of aminoglycosides to protect against another RNA virus 194 infection -Zika virus (ZIKV). ZIKV replicates in the vagina of wild-type mice and is 195 controlled by IRF3 and IRF7-dependent type I IFN secretion and IFNAR signaling 20 . Given 196 the ability of aminoglycosides to induce ISGs, we examined if aminoglycoside-treated 197 hosts are protected against ZIKV infection. We found that kasugamycin and neomycin 198 treatment resulted in significantly lower levels of ZIKV RNA in the vaginal mucosa early in 199 infection (Fig. 3c) . Notably, while vaginal ZIKV titers in neomycin-treated mice eventually 200 reached levels observed in PBS-treated controls, ZIKV replication in kasugamycin-treated 201 mice remained significantly lower in a large proportion of mice in this group (Fig. 3c) . 
signaling. 212
Since neomycin treatment resulted in increased expression of genes in nucleic acid 213 sensing pathways, we asked if cytosolic or endosomal nucleic acid sensing pathways were 214 involved. To test the requirement of cytosolic nucleic acid sensors, mice lacking the RIG-I 215 like receptor signaling adaptor Mavs, or the cytosolic DNA sensor cGAS, and its 216 downstream adapter STING (Tmem173) were treated with neomycin or PBS and 217 subsequent vaginal gene expression was examined. While neomycin induction of ISG 218 expression was intact in cGAS or STING knockout mice, neomycin-treated MAVS 219 knockout hosts showed relatively lower levels of ISG induction ( Supplementary Fig. 5a,d) . 220
Infection of neomycin-treated MAVS knockout hosts resulted in reduced protection 221 ( Supplementary Fig. 5b,c) . By contrast, neomycin-treatment of STING knockout mice 222 resulted in robust antiviral protection with significantly suppressed viral replication and little 223 to no disease pathology ( Supplementary Fig. 5e,f Fig. 6a,b) , 231
we found that treatment of Tlr3 -/-mice with neomycin resulted in no ISG induction (Fig. 4a ) 232 and this was accompanied by significant loss of protection against HSV-2 infection with 233 higher disease score and vaginal viral titers (Fig. 4b,c) (Fig. 4d ). This lack of 237 ISG induction was accompanied by a lack of protection against genital HSV-2 infection, as 238 neomycin-treated Trif -/-mice had equivalent vaginal viral titers and similar disease scores 239 as compared to PBS controls (Fig. 4e,f) 
Irf7
-/-mice as compared to PBS-treated controls ( Fig. 4g ) and this lack of ISG 245 induction resulted in lack of protection against HSV-2 infection (Fig. 4h,i) Supplementary Fig. 7a ). However, since basal ISG 250 expression was much lower in Ifnar1 -/-mice as compared to WT, neomycin treatment only 251 increased gene expression to those of untreated WT mice, thus neomycin treatment was 252 not accompanied by significant antiviral protection ( Supplementary Fig. 7b,c) 25 . Treatment with PTX ablated the protective effect of 266 neomycin as mice treated with both pertussis toxin and neomycin prior to infection had 267 significantly reduced vaginal ISG expression compared to PTX-untreated mice (Fig. 5a) . 268
This absence of ISG expression resulted in significantly higher levels of mucosal viral titers 269 and an increase in disease pathology upon HSV-2 infection (Fig. 5b,c) . These results 270 suggested that cellular recruitment to the vaginal tissue is prerequisite to the enhanced 271 ISG induction and protection against HSV-2 conferred by topical neomycin treatment. 272
To determine the specific cell types recruited to the vaginal mucosa upon neomycin 273 treatment, we compared the cellular composition of the vaginal mucosa in mice treated 274 with neomycin and those treated with neomycin and PTX. Monocytes (CD11b+), 275 monocyte-derived DCs (CD11b+CD11c+) and classical DCs (CD11c+), were significantly 276 increased upon neomycin treatment (Fig. 5d,e) . However, PTX treatment of neomycin-277 inoculated mice resulted in significant blockade of CD11c+ and CD11b+CD11c+ cells (Fig.  278 5e), suggesting that one or both of these cell types might be responsible for the neomycin-279 induced ISGs in the vaginal mucosa. 280
To test this hypothesis, we isolated CD11c+ cells from the vaginal tissue of neomycin-281 treated and control mice and found significant increases in transcripts of ISGs 282
( Supplementary Fig. 8 ). Likewise, these recruited CD11c+ cells were also found to express 283 IFNb ( Supplementary Fig. 9a ). To determine whether DCs are required for the increase in 284 ISG expression following neomycin application, we treated CD11c-DTR mice with 285 diphtheria toxin to deplete DCs and then administered neomycin intravaginally. In the 286 absence of DCs, neomycin treatment failed to increase vaginal ISG expression (Fig. 5f) . classical DCs are recruited to the vaginal mucosa, we wondered if TLR3 expression could 294 be used to identify the specific DC subset involved. It is well known that TLR3 is expressed 295 selectively by the cDC1 and not cDC2 (Refs. 26, 27 ). Examining TLR3 expression across all 296 DC subsets using the RNA sequencing datasets deposited in the Immunological Genome 297 project 28 confirmed a single cDC subset with high levels of TLR3 expression -CD8a+ 298 DCs (cDC1) from the thymus and spleen (Supplementary Fig. 10 ). In non-lymphoid tissue, 299 these cells are characterized as CD103+ DCs and both subsets express high levels of 300 TLR3 (Ref. 29 ). Recent studies have identified XCR1 as a defining cell surface marker for 301 cDC1 subset 30 . Thus, we measured the recruitment of XCR+CD103+ DCs in the vaginal 302 mucosa. Neomycin treatment resulted in significant recruitment of CD103+ XCR1+DCs 303 that were ablated upon treatment with pertussis toxin (Fig. 6a, These data led us to hypothesize that aminoglycosides may bind to dsRNA and render 334 them more potent for TLR3 activation. To test this, we treated splenocytes with a 335 combination of aminoglycosides and dsRNA Poly I:C. We found that a 1:1000 ratio of Poly 336 I:C to kasugamycin significantly induced ISG expression at greater levels than either 337 compound alone ( Supplementary Fig. 13 ). This enhancement was dependent on both 338 TLR3 and TRIF signaling ( Supplementary Fig. 13 ). Collectively, these data indicate that at 339 high molar ratio, kasugamicin synergizes with dsRNA to stimulate TLR3. Fig. 13 ). Future studies are needed to identify 397 the manner in which aminoglycoside-bound RNA stimulate TLR3. 398
Our results demonstrate a surprising and broad antiviral effect of the aminoglycoside 399 family of antibiotics, when applied to mucosal surfaces. However, we do not advocate for 400 use of these compounds as antivirals, as aminoglycoside application is expected to cause 401 local dysbiosis of commensal bacterial community. Understanding the precise mechanism 402 by which aminoglycosides induce TLR3 stimulation will be useful for the future design of 403 Mouse infections and antibiotic treatment: C57BL/6 mice between six and seventeen 430 weeks of age were subcutaneously injected with 2 milligrams of Depo-Provera in the neck 431 scruff. Five days after Depo treatment, the mice were vaginally swabbed with a calcium 432 alginate swab (Puritan, Maine) to remove vaginal mucus. The swab was wetted in sterile 433 PBS and blotted on sterile paper to get rid of excess liquid before being used. Ten to 15 434 microliters of antibiotic or PBS was delivered into the vaginal cavity using a pipette tip. 435
After 2-6 days of daily antibiotic treatment, mice were infected intravaginally with 2 x 10 3 to 436 5 x 10 3 PFU HSV-2, 10 6 PFU HSV-1 or 2.5 × 10 5 PFU ZIKV. Infections were carried out 437 24 hours after the last antibiotic treatment. In-vitro treatments: Single cell splenocytes were plated at the density of 5´10 6 cells/ml 519 isolated and treated with kasugamycin (2mg/ml or 0.02mg/ml) and PolyI:C (High Molecular 520
Weight, Invivogen,CA) (2µg/ml or 0.02µg/ml) for 6 hours. Mixtures of PolyI:C and 521 kasugamycin were incubated together for 30 minutes at 37°C before addition to cells. In 522 Supplementary Fig. 13 , splenocytes were treated for 12 hours, washed 5 times, stained 523 with cell trace violet (Thermo Fisher, CA), and incubated with splenic DCs isolated using 524 PanDC separation kit (Stemcell Technologies, MA). After 6 hour incubation, cell trace 525 violet dim and negative cells were sorted using an FACSAria (BD, NJ) into RLT buffer for 526
RNA extraction. 527
Statistics: Gene expression data was analyzed using unpaired t-tests, assuming unequal 528 standard deviation and correcting for multiple comparisons using the Holm-Sidak 529 correction unless otherwise specified. Graphs depicting disease scores were analyzed 530 using 2-way ANOVA with Holm-Sidak correction for multiple comparisons. Graphs 531 depicting viral titers across a time course of infection were analyzed using 2-way ANOVA 532 with no correction for multiple comparisons (Fisher's LSD) unless otherwise specified. 533 Survival curves were analyzed using the log-rank (Mantel-Cox) test. P values not reported 534 in the figures themselves can be found in Supplementary qPCR and all comparisons were made against PBS samples (d). Depo-treated mice were 717 treated intravaginally with 1 mg of the indicated aminoglycosides daily for 6 days and then 718 infected with HSV-2 (e,f). Disease score was monitored (e) and vaginal viral titers 719 measured (f). Error bars represent SEM and statistical significance was calculated using 720 2-way ANOVA. Exact p values for all comparisons are reported in Table S2 . 721 Table S2 . 738 measured (a,d,g ). In an 742 independent experiment these mice were infected with HSV-2, disease scores (b,e,h) and 743 vaginal viral titers measured (c,f,i). 129S1´B6 F2 mice were used as wild type controls for 744
TLR3
-/-mice (b,c) and C57BL/6N mice were used as wildtype controls for remaining (a,d-i). 745
Error bars represent SEM. Significance was calculated using 2-way ANOVA (b,e,h) or 746 unpaired t-tests correcting for multiple comparisons. Exact p values for all comparisons are 747 reported in Table S2 . 748 Mice treated subcutaneously with Depo-Provera were inoculated intravaginally with the indicated aminoglycoside (1mg) or PBS daily for 1 week. After 1 week of treatment, mice were infected with HSV-2. Viral titers in the vagina were measured at indicated time points (a-c). Viral titers in the dorsal root ganglion were measured 4 days post infection (d). Error bars represent SEM and signi cance was calculated using unpaired t-tests. Exact p values are reported in Table S2 . Depo-treated outbred germ-free swiss-webster mice (n=4-5) were treated with 1mg neomycin or PBS daily for 6 days and vaginal gene expression analyzed. Error bars represent SEM and statistical signi cance was determined using a one-way ANOVA with * representing p values < 0.05. Exact p values are reported in Table S2 . Mice treated subcutaneously with Depo-Provera were inoculated intravaginally with neomycin (1mg or 4.5 mgs) or PBS for 1 day (n = 3-5 mice per group). 24 hours later, vaginal gene expression was quanti ed. Depo-treated mice were innoculated intravaginally with neomycin (1mg/day) or PBS daily for 6 days. Mice were sacri ced 1,3 and 7 days after the last neomycin treatment as shown in (b) and vaginal gene expression analyzed at each time point (c). Depo-treated mice were inncoluated with 1mg neomycin daily for 6 days and vaginal and lung ISG expression analyzed in mice 1 day post neomycin treatment (d). Error bars represent SEM and signi cance was calculated using unpaired t-tests, corrected for multiple comparison. Exact p values are reported in Table S2 . Depo-treated Tlr7 -/-mice were treated intravaginally with neomcyin (1mg/day) for 6 days and then infected with HSV-2 and disease scores monitored (a) and vaginal viral titer measured (b). Error bars represent SEM and statistical signi cance was calculated using 2-way ANOVA (a,b). Speci c p values are reported in Table S2 . ) and accompanying WT controls were treated subcutaneously with Depo-Provera and treated intravaginally with neomycin (1mg) or PBS daily for 6 days and vaginal gene expression measured via qPCR (a). In an independent experiment neomycin-treated Ifnar1 -/-mice and PBS-treated controls were also infected with HSV-2, disease score monitored daily (b) and vaginal viral titers measured (c). Error bars represent SEM and signi cance was calculated using either unpaired t-tests (a) or 2-way ANOVA (b,c) correcting for multiple comparisons. Exact p values for all comparisons are reported in Table S2 . Mice treated subcutaneously with Depo-Provera were inoculated intravaginally with PBS or neomycin (1mg) for one week. Vaginal tissue from neomycin-treated and PBS control mice was xed, embedded and stained with hematoxylin and eosin. Images are magni ed 200X (a). Splenocytes were treated with 2mg/ml kasugamycin for 6 hours and dead cells were quanti ed using xable live/dead stain as a frequency of total leukocytes (c) or total cells (d). In an independent experiment kasugamycin-treated splenocytes were depleted of DCs and ISG expression quanti ed (e). Error bars represent SEM and exact p values are reported in Table S2 . Splenocytes were treated with2mg/ml kasugamycin for 12 hours, washed thoroughly, stained with cell trace violet and incubated with DCs isolated from WT or Tlr3 -/-splenocytes. After 6 hours of incubation, DCs (cell trace violet dim and negative cells) were sorted, RNA extracted and ISG expression quanti ed. Error bars represent SEM and speci c p values are detailed in Table S2 . Splenocytes from WT, Trif -/-or Tlr3 -/-mice were treated with 0.02μg/ml Poly I:C, 0.02mg/ml kasugamycin or the two together for 6 hours and ISG expression quanti ed. Error bars represent SEM and signi cance was calculated using a 2-way ANOVA. Speci c p values are reported in Table S2 .
